17,261 trials
Congenital Hyperinsulinism (CHI) · Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Primary: Accuracy of 18F-DOPA PET/CT Scans to Detect Focal Lesions in Children With Congenital Hyperinsulinism — 34; 10; 4; 52 cases
Post Surgical Ocular Inflammation
Primary: Assessment of Both Systemic and Ocular Adverse Events — 0; 3; 0; 0 Number of TEAE
Group B Streptococcal Infections
Primary: Percentage of Participants Reporting Prompted Local Reactions Within 14 Days Following Booster Dose (Redness, Swelling, and Pain at the Injection Site) — 68.4; 42.7…
Fanconi Anemia
Primary: Number of Participants Experiencing Graft Failure — 0; 0; 0 Participants
Alzheimer's Disease
Primary: Number of Patients With Adverse Events — 18 Participants
Phenylketonuria
Primary: Change From Baseline in the Blood Phenylalanine (Phe) Concentration — 1022.4; -553.5; -653.3; -672.3 μmol/L
Leber's Hereditary Optic Neuropathy
Primary: Double Masked Period: Incidence of Ocular TEAEs — 3; 8; 1; 3 eyes
Pain · Inflammation
Primary: Assessment of Pain — 30; 13; 2; 0 Participants
Soft Tissue Sarcoma
Primary: Phase 1b: Number of Participants With Dose Limiting Toxicity (DLT) — 1; 4; 3 Participants
Hypertension
Primary: Change From Baseline in Mean Daytime Systolic Blood Pressure (SBP) as Measured by Ambulatory Blood Pressure Monitoring (ABPM) at Day 28 — 1.38; -1.42; -3.28; -5.59…
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of BAL101553 — 70 mg/m²
Schizophrenia · Alcohol Use Disorder
Primary: Number of Participants With Independent Adjudication Committee (IAC) Adjudicated Event of Exacerbation of Disease (EEDS) — 25; 29; 87; 88 Participants — p=0.746
Colorectal Cancer
Primary: Median Progression Free Survival (mPFS) — 8.8 months
Subarachnoid Hemorrhage
Primary: Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug — 1; 1 Participants
Staphylococcus Aureus Bacteremia · Staphylococcus Aureus Endocarditis
Primary: Incidence of Adverse Events [Safety and Tolerability] — 48; 30; 64; 40 Participants